Tscan Therapeutics Inc Capital Reinvestment Ratio

Latest as of September 2023: 0.18x

Tscan Therapeutics Inc capital reinvestment ratio. Tscan Therapeutics Inc (TCRX) has a Capital Reinvestment Ratio of 0.18x as of September 2023, meaning it reinvests 0% of its operating cash flow ($8.02 Million) in capital expenditures ($1.42 Million). Check cash flow reinvestment rate of Tscan Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

0.18x

Capex / Operating Cash Flow

Operating Cash Flow

$8.02 Million

USD

Capital Expenditures

$1.42 Million

USD

Data as of

Sep 2023

Most recent filing

Tscan Therapeutics Inc Capital Reinvestment Ratio by Year (None–None)

Tscan Therapeutics Inc capital reinvestment ratio by year from None to None. For the full cash flow conversion analysis, see cash flow conversion of Tscan Therapeutics Inc.

Year	Reinvestment Ratio	Operating CF (USD)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow